Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma

Relin Yang, Michael C. Cheung, Margaret M Byrne, Xiaoling Jin, Alberto J. Montero, Catherine Jones, Leonidas G. Koniaris

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The survival benefit of adjuvant chemotherapy alone or chemoradiotherapy in patients with pancreatic cancer who have undergone surgical resection remains unclear. Objective: To identify the additional benefit of adjuvant therapy by retrospectively examining a large population-based registry of patients who underwent definitive surgical resection for pancreatic adenocarcinoma. Design and Setting: The Florida cancer registry and state inpatient and outpatient hospital data records were queried for pancreatic adenocarcinoma diagnosed between 1998 and 2002. Patients: A total of 2877 patients who underwent surgical resection with curative intent for pancreatic adenocarcinoma were identified. Main Outcome Measure: Overall survival time. Results: Overall, 58.7% of patients were older than 65 years. Most patients were white (90.7%), were non-Hispanic (86.7%), and did not consume alcohol abusively (89.2%). Approximately half of the patients (51.9%) did not receive chemotherapy or chemoradiotherapy. Approximately 25.0% of the patients underwent chemoradiotherapy, and 10.0% received chemotherapy alone. Patients were more frequently treated at low-volume centers (57.6%) and nonteaching facilities (72.8%). Multivariate analysis correcting for patient comorbidities demonstrated that postoperative chemoradiotherapy (hazard ratio=0.69, P=.04) and treatment at high-volume centers (hazard ratio=0.85, P<.001) and teaching facilities (hazard ratio=0.84, P<.001) were independent predictors of improved survival. Conclusions: Adjuvant chemoradiotherapy was found to provide a significant additional survival benefit to surgical resection for patients with pancreatic adenocarcinoma. Furthermore, this benefit is independent of the additional survival advantage when patients are treated at teaching facilities or high-volume centers. Although selection bias may be contributing to the observed differences, these data nonetheless support the use of adjuvant chemoradiotherapy for pancreatic cancer.

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalArchives of Surgery
Volume145
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Adjuvant Chemoradiotherapy
Survival
Adenocarcinoma
Chemoradiotherapy
Pancreatic Neoplasms
Registries
Pancreatic Carcinoma
Teaching
Drug Therapy
Hospital Records
Selection Bias
Adjuvant Chemotherapy

ASJC Scopus subject areas

  • Surgery

Cite this

Yang, R., Cheung, M. C., Byrne, M. M., Jin, X., Montero, A. J., Jones, C., & Koniaris, L. G. (2010). Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. Archives of Surgery, 145(1), 49-56. https://doi.org/10.1001/archsurg.2009.244

Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. / Yang, Relin; Cheung, Michael C.; Byrne, Margaret M; Jin, Xiaoling; Montero, Alberto J.; Jones, Catherine; Koniaris, Leonidas G.

In: Archives of Surgery, Vol. 145, No. 1, 01.01.2010, p. 49-56.

Research output: Contribution to journalArticle

Yang, R, Cheung, MC, Byrne, MM, Jin, X, Montero, AJ, Jones, C & Koniaris, LG 2010, 'Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma', Archives of Surgery, vol. 145, no. 1, pp. 49-56. https://doi.org/10.1001/archsurg.2009.244
Yang, Relin ; Cheung, Michael C. ; Byrne, Margaret M ; Jin, Xiaoling ; Montero, Alberto J. ; Jones, Catherine ; Koniaris, Leonidas G. / Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. In: Archives of Surgery. 2010 ; Vol. 145, No. 1. pp. 49-56.
@article{0bad5327c6924686bebe01197ac41e06,
title = "Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma",
abstract = "Background: The survival benefit of adjuvant chemotherapy alone or chemoradiotherapy in patients with pancreatic cancer who have undergone surgical resection remains unclear. Objective: To identify the additional benefit of adjuvant therapy by retrospectively examining a large population-based registry of patients who underwent definitive surgical resection for pancreatic adenocarcinoma. Design and Setting: The Florida cancer registry and state inpatient and outpatient hospital data records were queried for pancreatic adenocarcinoma diagnosed between 1998 and 2002. Patients: A total of 2877 patients who underwent surgical resection with curative intent for pancreatic adenocarcinoma were identified. Main Outcome Measure: Overall survival time. Results: Overall, 58.7{\%} of patients were older than 65 years. Most patients were white (90.7{\%}), were non-Hispanic (86.7{\%}), and did not consume alcohol abusively (89.2{\%}). Approximately half of the patients (51.9{\%}) did not receive chemotherapy or chemoradiotherapy. Approximately 25.0{\%} of the patients underwent chemoradiotherapy, and 10.0{\%} received chemotherapy alone. Patients were more frequently treated at low-volume centers (57.6{\%}) and nonteaching facilities (72.8{\%}). Multivariate analysis correcting for patient comorbidities demonstrated that postoperative chemoradiotherapy (hazard ratio=0.69, P=.04) and treatment at high-volume centers (hazard ratio=0.85, P<.001) and teaching facilities (hazard ratio=0.84, P<.001) were independent predictors of improved survival. Conclusions: Adjuvant chemoradiotherapy was found to provide a significant additional survival benefit to surgical resection for patients with pancreatic adenocarcinoma. Furthermore, this benefit is independent of the additional survival advantage when patients are treated at teaching facilities or high-volume centers. Although selection bias may be contributing to the observed differences, these data nonetheless support the use of adjuvant chemoradiotherapy for pancreatic cancer.",
author = "Relin Yang and Cheung, {Michael C.} and Byrne, {Margaret M} and Xiaoling Jin and Montero, {Alberto J.} and Catherine Jones and Koniaris, {Leonidas G.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1001/archsurg.2009.244",
language = "English",
volume = "145",
pages = "49--56",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma

AU - Yang, Relin

AU - Cheung, Michael C.

AU - Byrne, Margaret M

AU - Jin, Xiaoling

AU - Montero, Alberto J.

AU - Jones, Catherine

AU - Koniaris, Leonidas G.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: The survival benefit of adjuvant chemotherapy alone or chemoradiotherapy in patients with pancreatic cancer who have undergone surgical resection remains unclear. Objective: To identify the additional benefit of adjuvant therapy by retrospectively examining a large population-based registry of patients who underwent definitive surgical resection for pancreatic adenocarcinoma. Design and Setting: The Florida cancer registry and state inpatient and outpatient hospital data records were queried for pancreatic adenocarcinoma diagnosed between 1998 and 2002. Patients: A total of 2877 patients who underwent surgical resection with curative intent for pancreatic adenocarcinoma were identified. Main Outcome Measure: Overall survival time. Results: Overall, 58.7% of patients were older than 65 years. Most patients were white (90.7%), were non-Hispanic (86.7%), and did not consume alcohol abusively (89.2%). Approximately half of the patients (51.9%) did not receive chemotherapy or chemoradiotherapy. Approximately 25.0% of the patients underwent chemoradiotherapy, and 10.0% received chemotherapy alone. Patients were more frequently treated at low-volume centers (57.6%) and nonteaching facilities (72.8%). Multivariate analysis correcting for patient comorbidities demonstrated that postoperative chemoradiotherapy (hazard ratio=0.69, P=.04) and treatment at high-volume centers (hazard ratio=0.85, P<.001) and teaching facilities (hazard ratio=0.84, P<.001) were independent predictors of improved survival. Conclusions: Adjuvant chemoradiotherapy was found to provide a significant additional survival benefit to surgical resection for patients with pancreatic adenocarcinoma. Furthermore, this benefit is independent of the additional survival advantage when patients are treated at teaching facilities or high-volume centers. Although selection bias may be contributing to the observed differences, these data nonetheless support the use of adjuvant chemoradiotherapy for pancreatic cancer.

AB - Background: The survival benefit of adjuvant chemotherapy alone or chemoradiotherapy in patients with pancreatic cancer who have undergone surgical resection remains unclear. Objective: To identify the additional benefit of adjuvant therapy by retrospectively examining a large population-based registry of patients who underwent definitive surgical resection for pancreatic adenocarcinoma. Design and Setting: The Florida cancer registry and state inpatient and outpatient hospital data records were queried for pancreatic adenocarcinoma diagnosed between 1998 and 2002. Patients: A total of 2877 patients who underwent surgical resection with curative intent for pancreatic adenocarcinoma were identified. Main Outcome Measure: Overall survival time. Results: Overall, 58.7% of patients were older than 65 years. Most patients were white (90.7%), were non-Hispanic (86.7%), and did not consume alcohol abusively (89.2%). Approximately half of the patients (51.9%) did not receive chemotherapy or chemoradiotherapy. Approximately 25.0% of the patients underwent chemoradiotherapy, and 10.0% received chemotherapy alone. Patients were more frequently treated at low-volume centers (57.6%) and nonteaching facilities (72.8%). Multivariate analysis correcting for patient comorbidities demonstrated that postoperative chemoradiotherapy (hazard ratio=0.69, P=.04) and treatment at high-volume centers (hazard ratio=0.85, P<.001) and teaching facilities (hazard ratio=0.84, P<.001) were independent predictors of improved survival. Conclusions: Adjuvant chemoradiotherapy was found to provide a significant additional survival benefit to surgical resection for patients with pancreatic adenocarcinoma. Furthermore, this benefit is independent of the additional survival advantage when patients are treated at teaching facilities or high-volume centers. Although selection bias may be contributing to the observed differences, these data nonetheless support the use of adjuvant chemoradiotherapy for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=74549216583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549216583&partnerID=8YFLogxK

U2 - 10.1001/archsurg.2009.244

DO - 10.1001/archsurg.2009.244

M3 - Article

C2 - 20083754

AN - SCOPUS:74549216583

VL - 145

SP - 49

EP - 56

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 1

ER -